KXII Health Headlines

Unapproved device buys time for new pair of lungs

Posted: 07/02/2014 - PITTSBURGH (AP) - An Oklahoma man is slowly gaining strength at a Pittsburgh hospital with a second set of transplanted lungs in a procedure that was possible only through a device that until now hasn't been used in the U.S.

Warning signs and how to prevent a drowning

Updated: 06/19/2014 - DENISON, TX -- As the temperatures rise in Texoma, lifeguards and emergency crews are concerned about an increase in drowning accidents as more people hit the water.

FDA prepping long-awaited plan to reduce salt

Posted: 06/17/2014 - WASHINGTON (AP) - Food companies and restaurants could soon face government pressure to make their foods less salty - a long-awaited federal effort to try to prevent thousands of deaths each year from heart disease and stroke.

Safe Family: BB gun problems

Posted: 05/22/2014 - IOWA -- An Iowa woman is warning parents about the dangers of BB guns. She was hit in the chest and it is now lodged in her body. Vanessa Peng has her story in today's safe family report.

Kids get codeine in ER despite risks, guidelines

Posted: 04/21/2014 - CHICAGO (AP) - Despite recommended limits on codeine use in children, the potent painkiller is prescribed for children in at least half a million emergency room visits each year, a study suggests.

More KXII Health Headlines

CBS News Health Headlines

WebMD Health News

AP Top Health Stories

  • LATAM Airlines says no Brazil sales impact yet from Zika worries

    Brazilian airline Tam's Airbus A320 takes off at Congonhas airport in Sao PauloBy Anthony Esposito and Felipe Iturrieta SANTIAGO (Reuters) - Concerns over the Zika virus have not affected ticket sales at LATAM Airlines' TAM Brazilian unit, the regional carrier said on Monday. "So far, there has been no impact on reservations at TAM ... due to the cases of Zika virus in Brazil and in other locations where the airline operates," Chile-headquartered LATAM said. The rapidly spreading Zika virus, suspected to be linked to thousands of birth defects in Brazil, appears to be discouraging some tourists from traveling to Latin America and the Caribbean.

  • Sientra says to resume selling its breast implant devices in U.S.
    (Reuters) - Breast implant maker Sientra Inc said it will resume selling all of its medical devices in the U.S. market from March 1, four months after it suspended sales of its breast implant devices to ensure technical compliance. The company had put a hold on sales of its implants in October, citing some technical compliance issues at Brazilian contract manufacturer Silimed's plant.
  • Europe creates Zika drug 'task force'

    The World Health Organization has declared the Zika outbreak a global medical emergencyEurope's medicines watchdog said Monday it had assembled an expert team to aid the development of drugs and vaccines against the Zika virus, feared to cause brain damage in unborn babies. The task force includes specialists in vaccine design and infectious diseases, the London-based European Medicines Agency (EMA) announced in a statement, and warned of a "widening public health crisis". "This group will be available to give advice on any scientific and regulatory matters for the research and development of medicines or vaccines against the virus," it said.

  • Cognizant forecasts slowest revenue growth in 14 years
    (Reuters) - IT services provider Cognizant Technology Solutions Corp forecast its slowest revenue growth in 14 years for the current quarter, as clients worldwide rein in IT spending. The top end of the revenue range indicates an 11.34 percent growth in the current quarter from a year earlier, its slowest since the March quarter of 2002. Analysts on average were expecting a profit of 81 cents per share and revenue of $3.32 billion for the first quarter, according to Thomson Reuters I/B/E/S. IT services companies have been focusing on high-margin digital technology and automation outsourcing contracts at a time when clients are cutting back on routine IT services spending.
  • Sarepta says FDA delays decision on muscle-wasting disorder drug
    (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder. The FDA has delayed the decision to May 26 from late February, the company said. The drug is designed to treat a subset of patients with Duchenne muscular dystrophy.
Sherman 4201 Texoma Pkwy (903) 892 -8123 Ardmore 2624 S. Commerce (580) 223-0946
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability
Gray Television, Inc.